Stem Cells Get a Big Boost from a Small Molecule

Erik Greb PharmTech editorThe pace of progress in stem-cell research seems to be quickening, and the field’s future looks promising. Last week, a team at the Harvard Stem Cell Institute found what looks like a revolutionary way to create stem cells that could be safe enough to use as treatments in humans. Read more »

Cancer Drug Delivery on Homing Device

Maribel Rios PharmTech editor

Prostate cancer remains one of the most common cancers and the second-leading cause of cancer death in American men, according to the American Cancer Society. So far, treatments for prostate cancer include drugs that affect the entire body, instead of only cancer cells. Work by a team of researchers at Purdue University offers hope they have found a new method of not only finding and targeting these cancer cells, but also carry therapeutic drugs directly to the site of infection. Read more »

Running Interference

Erik Greb PharmTech editorReading the wires every day reinforces my impression that biological drugs are an evolving field that may soon become a major segment of the pharmaceutical industry. But a new report from Research and Markets reminded me that a form of gene therapy also promises interesting discoveries and potential cures. Read more »

Roll Up Your Sleeves: Human Genome Sequencing Begins

Maribel Rios PharmTech editorIt has long been predicted that breakthroughs in genomics will foster an entirely new generation of pharmaceutical and biopharmaceutical therapies. Now, five and a half years after the Human Genome Project published the full sequence human genome, the first population-wide study to gather human genetic data is set to begin. Read more »

Born under a Bad Sign

Erik Greb PharmTech editor

I’m not an astrologist, but sometimes you have to wonder whether plans were hatched under a bad sign. It certainly seems that way for “Vytorin,” a cholesterol-lowering drug that combines simvastatin and “Zetia.” The drug, introduced by Merck and Schering-Plough, has suffered damaging revelations. Read more »

A Dose Deferred

Erik Greb Pharmtech editorSeven months after Pfizer (New York) pulled “Exubera” from the market, the star-crossed product’s saga continues. Pfizer apparently plans to close its Terre Haute, Indiana, manufacturing facility, which had gotten a cash infusion to prepare it to produce—you guessed it—Exubera. The company insists that the plant closure is unrelated to Exubera’s failure, but I find that hard to believe.

Is this plant closure the final nail in the coffin of inhaled insulin?

Read more »

Biology is Perverse, Part I

hoffman.jpgPeople always giggle when I say that, but it’s true. Of all the “basic” sciences, biology is the most slippery. By that I mean that, while the tendency is to study biomolecules and cells in isolation, the total animal, be it a bacterium or a human being, is a federation of molecules, organelles, or organs (depending on how big and multicellular you are), and they all act together to create a phenotype, a behavior, a syndrome, or a disease in the intact organism.
So it should hardly be a surprise to anyone who recognizes this fact that drugs for complex conditions, developed with reductionist biological models, yield disappointing results in the clinic. And yet it is. Read more »

« Previous Page